E
EWTX
Edgewise Therapeutics, Inc.
44.18
+0.89+2.06%After Hours: 44.18 0.00 0.00%19:30 08/21 EDT
OPEN/PREV CLOSE43.54/43.29
TODAY RANGE43.00-44.68
VOL1.25M
MARKET CAP4.80B
52 WEEK RANGE13.53-48.40
AVG VOL (3M)1.46M
% TURNOVER1.15%
TURNOVER--
P/E (TTM)-23.8940
% RANGE3.87%
EPS(TTM)-1.8490
P/E(FORWARD)26.26
P/B10.63
BVPS4.158
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.90B
SHARES OUTSTANDING108.60M
NEXT EARNINGS11/04-11/09
FREE FLOAT88.17M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·2d ago
Edgewise Therapeutics Is Maintained at Overweight by JP Morgan
Simply Wall St·3d ago
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?
Simply Wall St·6d ago
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich
Dow Jones·08/11 18:02
Edgewise Therapeutics Is Maintained at Neutral by Goldman Sachs
TipRanks·08/11 10:15
Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
TipRanks·08/06 21:20
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
Benzinga·08/06 12:45
Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate
Seeking Alpha·08/06 12:15
Edgewise Therapeutics GAAP EPS of -$0.53
TipRanks·08/05 16:30
Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors
TipRanks·07/31 16:30
Edgewise Therapeutics Marks Key Milestone With EDG-7500 Phase 1 Completion
Seeking Alpha·07/21 17:26
Tracking Baker Brothers Portfolio: Q1 2026 Update
Same Industry
Name/Symbol
Change%
Price